Vous venez de lire:

Health Canada Approves XTANDI® (enzalutamide) - the First and Only Oral Treatment for Men with Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer

Nouvelles fournies par

Astellas Pharma Canada, Inc.

Janv 14, 2019, 08:00 ET